WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory Challenges
Abrir esta carpeta y ver su contenidoEssential Medicines
Cerrar esta carpetaSafety and Efficacy Issues
Ver el documentoSafety of HIV therapies targeted by new advisory committee
Ver el documentoThe risks and benefits of HRT
Ver el documentoMacrolides and warfarin interaction
Ver el documentoStatin risk factors: myopathy and rhabdomyolysis
Ver el documentoSerotonin syndrome
Ver el documentoAntidepressants: worsening depression and suicidal behaviour
Ver el documentoUse of SSRI antidepressants in children and adolescents
Ver el documentoRepaglinide and gemfibrozil interaction
Abrir esta carpeta y ver su contenidoVaccines and Biomedicines
Abrir esta carpeta y ver su contenidoHerbal Medicines
Abrir esta carpeta y ver su contenidoRegulatory and Safety Action
Abrir esta carpeta y ver su contenidoConsultation Document
Ver el documentoProposed International Nonproprietary Names: List 90
Ver el documentoRecommended International Nonproprietary Names: List 51
 

Macrolides and warfarin interaction

The Australian Drug Evaluation Committee (ADRAC) has received reports of interactions between warfarin and all four macrolide antibiotics (azithromycin, clarithromycin, erythromycin, and roxithromycin) (see table below) (1). Although most cases were asymptomatic, some reports documented substantial increases in INR. The haemorrhagic complications reported included haematoma, haemoptysis, haematuria, melaena, and retroperitoneal haemorrhage.

Close attention should be paid to INR monitoring in patients taking warfarin who are commenced on a macrolide antibiotic. Consideration could also be given to the use of an alternative antibiotic if possible. Azithromycin has a particularly long half-life (around 68 hours), so that an interaction with warfarin may theoretically persist for some days after azithromycin has been ceased.

Extracted from Australian Adverse Drug Reactions Bulletin, Volume 23, Number 2, April 2004

Reference

1. Australian Adverse Drug Reactions Bulletin, 14: 11 (1995).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012